FDA's review of MDMA for PTSD highlights study bias and safety concerns
MDMA for PTSD therapy efficacy is under FDA review due to flawed trials and safety concerns, marking a potential shift in federal policy.
Psychedelic drug MDMA faces questions as FDA considers approval for PTSD
Psychedelic drug MDMA's potential as PTSD treatment raises safety concerns
MDMA faces FDA panel in bid to become first-of-a-kind PTSD medication
FDA considering MDMA for PTSD treatment. MDMA could be first illegal psychedelic to gain medical approval, paving way for other psychedelics. Challenges in studying and assessing psychedelic drugs.
FDA's Rejection of MDMA Psychotherapy for Trauma Draws Criticism from Psychedelic Experts
The FDA did not approve MDMA for PTSD therapy, requiring an additional clinical trial.
The FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients.
FDA's proposed restrictions on MDMA for PTSD patients include monitoring safeguards and restricted administration at healthcare facilities.
FDA advisors express skepticism as they debate MDMA therapy for PTSD
MDMA-assisted therapy for PTSD may soon be considered safe and effective, potentially entering mainstream healthcare.
FDA's review of MDMA for PTSD highlights study bias and safety concerns
MDMA for PTSD therapy efficacy is under FDA review due to flawed trials and safety concerns, marking a potential shift in federal policy.
Psychedelic drug MDMA faces questions as FDA considers approval for PTSD
Psychedelic drug MDMA's potential as PTSD treatment raises safety concerns
MDMA faces FDA panel in bid to become first-of-a-kind PTSD medication
FDA considering MDMA for PTSD treatment. MDMA could be first illegal psychedelic to gain medical approval, paving way for other psychedelics. Challenges in studying and assessing psychedelic drugs.
FDA's Rejection of MDMA Psychotherapy for Trauma Draws Criticism from Psychedelic Experts
The FDA did not approve MDMA for PTSD therapy, requiring an additional clinical trial.
The FDA is weighing whether to approve MDMA for PTSD. Here's what that could look like for patients.
FDA's proposed restrictions on MDMA for PTSD patients include monitoring safeguards and restricted administration at healthcare facilities.
FDA advisors express skepticism as they debate MDMA therapy for PTSD
MDMA-assisted therapy for PTSD may soon be considered safe and effective, potentially entering mainstream healthcare.
Startups Are Biohacking Psychedelic Drugs to Make Sure You Never Have a Bad Trip Again
Pharmaceutical companies are developing next-generation psychedelics to serve as safer psychotherapy treatments, with promising early research on compounds like R-MDMA.
The drugmaker that hopes to legalize MDMA is cutting 75% of its staff after the FDA rejected the drug
Lykos Therapeutics is reducing its staff by 75% after the FDA rejected its MDMA drug for mental health treatment.
Startups Are Biohacking Psychedelic Drugs to Make Sure You Never Have a Bad Trip Again
Pharmaceutical companies are developing next-generation psychedelics to serve as safer psychotherapy treatments, with promising early research on compounds like R-MDMA.
The drugmaker that hopes to legalize MDMA is cutting 75% of its staff after the FDA rejected the drug
Lykos Therapeutics is reducing its staff by 75% after the FDA rejected its MDMA drug for mental health treatment.
MDMA combined with therapy may become a legal part of modern medicine, marked by FDA advisory committee review after years of study and transformation.
FDA rejects ecstasy as a therapy: what's next for psychedelics?
FDA rejected MDMA for psychiatric treatment, prompting questions about future psychedelic therapies.
FDA Advisors Recommend Against Using MDMA for PTSD Treatment
Panel of FDA experts voted against MDMA use for PTSD treatment due to lack of evidence and risk-benefit concerns.
Psychedelics Have a Placebo Problem
Studying mind-altering drugs like psychedelics faces challenges due to inability to blind participants, potentially impacting research validity.
Opinion | How Psychedelic Research Got High on Its Own Supply
Lykos Therapeutics faced a significant setback with the F.D.A.'s rejection of their MDMA PTSD treatment application, raising concerns about trial integrity.
How Selling Out' helped psychedelic MDMA
MDMA combined with therapy may become a legal part of modern medicine, marked by FDA advisory committee review after years of study and transformation.
FDA rejects ecstasy as a therapy: what's next for psychedelics?
FDA rejected MDMA for psychiatric treatment, prompting questions about future psychedelic therapies.
FDA Advisors Recommend Against Using MDMA for PTSD Treatment
Panel of FDA experts voted against MDMA use for PTSD treatment due to lack of evidence and risk-benefit concerns.
Psychedelics Have a Placebo Problem
Studying mind-altering drugs like psychedelics faces challenges due to inability to blind participants, potentially impacting research validity.
Opinion | How Psychedelic Research Got High on Its Own Supply
Lykos Therapeutics faced a significant setback with the F.D.A.'s rejection of their MDMA PTSD treatment application, raising concerns about trial integrity.
The FDA Didn't Approve MDMA. Is the Medical System Ready for Any Psychedelic?
FDA rejected MDMA for PTSD therapy due to insufficient data, raising doubts about psychedelics' future in U.S. medical system.
MDMA trials are showing it has promise as a psychiatric medicine | Letters
Proper funding needed for integrated mental health care. MDMA and psychedelics show promise in psychiatric medicines based on evidence and controlled trials.
The FDA Didn't Approve MDMA. Is the Medical System Ready for Any Psychedelic?
FDA rejected MDMA for PTSD therapy due to insufficient data, raising doubts about psychedelics' future in U.S. medical system.
MDMA trials are showing it has promise as a psychiatric medicine | Letters
Proper funding needed for integrated mental health care. MDMA and psychedelics show promise in psychiatric medicines based on evidence and controlled trials.
This man could be about to make MDMA legal for therapy. Are we ready for it?
Rick Doblin founded Maps in 1986 to advocate for the legal use of psychedelics for mental health and spiritual purposes. Maps has focused on mainstreaming MDMA for therapeutic use.
A raft of unanswered questions' remain as Australia's first psychedelic therapy clinic opens
Australia's first psychedelic therapy clinic has opened, offering MDMA and psilocybin treatments for PTSD and depression.
The decision to legalize medical use of psychedelics in Australia has raised concerns about the influence of lobby groups over health experts.
This man could be about to make MDMA legal for therapy. Are we ready for it?
Rick Doblin founded Maps in 1986 to advocate for the legal use of psychedelics for mental health and spiritual purposes. Maps has focused on mainstreaming MDMA for therapeutic use.
A raft of unanswered questions' remain as Australia's first psychedelic therapy clinic opens
Australia's first psychedelic therapy clinic has opened, offering MDMA and psilocybin treatments for PTSD and depression.
The decision to legalize medical use of psychedelics in Australia has raised concerns about the influence of lobby groups over health experts.